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1tatins to Reduce Risk of Depression
e read with great interest the findings by Young-Xu and
o-workers on long-term use of statins to reduce the risk of
epression (1). Patients treated with statins had a lower incidence
f abnormal psychological scores. A 30% to 40% risk reduction for
epression was found in this group. At first glance, the effect of
tatins appears to relate to cholesterol reduction. However, in
ddition to inhibition of HMG-CoA reductase, certain statins
ere found to suppress the Th1-type cytokines interferon-gamma
IFN-) and interleukins (IL)-2 and -12, while promoting secre-
ion of Th-2 cytokines IL-4, IL-5, and IL-10 (2). Such data
avorably compare to results we have generated in vitro on
torvastatin to suppress IFN--mediated biochemical events in
eripheral blood mononuclear cells and in monocytes (3). Atorva-
tatin was shown to diminish in a dose-dependent manner activity
f indoleamine (2,3)-dioxygenase (IDO). Enzyme IDO is induc-
ble by IFN- and degrades the essential amino acid tryptophan via
he kynurenine pathway. Therefore, accelerated tryptophan deg-
adation by IDO activation is commonly observed in a broad range
f diseases associated with endogenous formation of Th1-type
ytokine IFN- (4), including patients with coronary heart disease
CHD) (5).
Because tryptophan is precursor of neurotransmitter
-hydroxytryptamine (serotonin), lowered tryptophan availability
ncreases the susceptibility of depression in patients (4); for
xample, in patients with colorectal cancer an association was
eported between lowered serum tryptophan related to immune
ctivation and impaired quality of life (6). Thus, when statins are
ble to block IDO and thereby increase tryptophan concentrations,
t is reasonable that statins would reduce the risk of depression in
HD patients with an accelerated tryptophan degradation (5).
hether statins improve tryptophan metabolism in patients is
orth being tested in clinical trials.
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e are pleased that Dr. Wirleitner and colleagues found our
eport (1) of interest. We would like to point out that in our study
he effects of statins on psychological well-being appeared to be
ndependent of both cholesterol reduction and baseline cholesterol
evel. Because the effects of statins on the psychological well-being
f our patients were related to the lipophilicity of the statin and not
o the level of cholesterol reduction, we postulate that the biolog-
cal effect may be mediated by statin’s direct effect on the central
ervous system. By inhibiting HMG-CoA reductase in neuronal
ells, statins could potentially alter cellular cholesterol content and
ipid membrane rafts. This could lead to changes in neuronal
unction as manifested in psychological well-being. Another con-
equence of HMG-CoA reductase inhibition is inhibition of
ignaling molecules that depend upon isoprenylation for proper
unction. In this respect, statins could alter the balance of Th1/
h2 cell population, leading to potential blockade of indoleamine
ioxygenase. Indeed, statins have been shown to decrease Th1-
ediated inflammatory response in an autoimmune mouse model
f multiple sclerosis (2). This effect was observed without signif-
cant changes in serum cholesterol levels. Thus, it is possible that
he “antidepressant” effect of statins in our patient population
ould be mediated by a cholesterol-independent immunomodula-
ory effect of statins.
We are encouraged by Dr. Wirleitner and colleagues’ letter,
hich supports our clinical observation by providing another clue
o a potential biological mechanism. We do agree with them that
t should be tested in clinical trials whether statins improve
ryptophan metabolism, as that would provide data to support or
efute the proposed biological mechanism.
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yocardial Bridging in Adult and Pediatric
atients With Hypertrophic Cardiomyopathy
s Not Associated With Poor Outcome
he recent report by Sorajja et al. (1) that myocardial bridging in
dults with hypertrophic cardiomyopathy (HCM) is not associated
ith an increased risk of sudden death is in agreement with our
wn study conducted in children (2), and is in contrast to the
uggestion that systolic coronary compression in pediatric patients
esults in myocardial ischemia and a poor prognosis (3).
Unfortunately, Sorajja et al. (1) misrepresent our findings. They
nclude our study with references that have associated myocardial
ridging with “nuclear perfusion abnormalities, chest pain, ven-
ricular tachycardia and an increased risk of sudden cardiac death.”
ur conclusions were directly the opposite: we found no associa-
ion between coronary bridging, symptoms, perfusion abnormali-
ies, ventricular arrhythmias, and sudden death. Rather, in multi-
ariate analyses, perfusion abnormalities were related to the
agnitude of left ventricular hypertrophy (LVH) and the presence
f septal artery compression. Unfortunately, Sorajja et al. did not
valuate angiograms for septal artery compression, and the associ-
tion between bridging and severity of LVH is not assessed in
atient groups of similar age. Finally, our study was conducted in
group of 57 pediatric patients, and not in only 23 as stated in the
urrent report.
The report by Sorajja et al. emphasizes our conclusions that it is
ery unlikely that systolic compression of epicardial coronary
rteries results in poorer outcome in HCM, and that there is
urrently no rationale for surgical or catheter-based correction (2).
he contribution made by septal artery compression, intraventric-
lar pressure, and LVH to perfusion abnormalities and therefore to
ymptoms and prognosis should be the focus of further investiga-
ion.
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e appreciate the interest of Drs. Mohiddin and Fananapazir in
ur recent publication on myocardial bridging in adult patients
ith hypertrophic cardiomyopathy (HCM) (1). We apologize for
ny misrepresentation of the data from their publication on
yocardial bridging in pediatric patients with HCM (2). The
tudy published by Mohiddin et al. was included in the list of
eferences that associated bridging with perfusion abnormalities, as
heir study had demonstrated such an association in univariate
nalyses. We emphasized the absence of this relation, in their
tudy, after adjustment for other clinical variables in order to
upport our conclusions that bridging is not associated with an
dverse prognosis.
Septal artery compression was not examined in our study.
owever, it is unlikely that this finding would be associated with
dverse outcomes as such compression is found in nearly all
atients with epicardial bridging, and there were no differences
ith respect to ventricular tachycardia or prognosis in the inves-
igators’ study (2). We observed no difference in maximal left
entricular wall thickness between patients with and without
ridging. Finally, the study by Drs. Mohiddin and Fananapazir did
xamine 57 pediatric HCM patients, of whom 23 had myocardial
ridging. We apologize for this typographical error.
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mbolic Complications in
treptococcus Viridans Endocarditis
n their editorial, entitled “Toward reducing embolic complica-
ions from endocarditis,” Drs. Homma and Grahame-Clarke
ndicated that the type of the organism may increase the likelihood
f embolization and that Streptococcus viridans and Staphylococcus
ureus endocarditis are associated with higher incidence of embo-
ization (1). Though this is correct for S. aureus endocarditis, S.
iridans endocarditis is not specifically associated with higher
ncidence of embolization (2,3). McLeod et al. (2), Cherubin et al.
3), and Utley et al. (4,5) found the highest incidence of emboli
ith fungus infection (60% to 100%), S. aureus (58%), and
eisseria (35%). Streptococcus species, including viridans, and
nterococci had a lower risk of embolization (15% to 25%). In their
ditorial, Homma and Grahame-Clarke quoted De Castro et al.
or higher embolization in S. viridans (6). However, De Castro et
l. showed in their series that only 6 out of 22 patients with
